Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Lupus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more

Conditions: Hypogonadism, Low Testosterone
Interventions: Androxal (enclomiphene citrate), Testim (topical testosterone); Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Garden Grove, California • Sacramento, California • San Diego, California + 2 more

Conditions: Menopause
Interventions: esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 78
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more

Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lacrimal Apparatus Disease, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions: Dehydroepiandrosterone; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypogonadism, Male
Interventions: Natesto; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Testosterone Deficiency
Interventions: Testosterone Therapy; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 20 Years to 90 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Healthy, Osteoporosis, Premature Ovarian Failure
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 32 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Testosterone Cypionate 100 MG/ML, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Mild Cognitive Impairment, Dementia, Mild
Interventions: Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management; Dietary Supplement · Combination Product · Behavioral
Lead sponsor: Alzheimer's Prevention and Reversal Project, Inc.; Other
Eligibility: 45 Years to 76 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Folsom, California • San Rafael, California • Walnut Creek, California + 3 more

Conditions: Peyronie's Disease
Interventions: Vitamin D2, Vitamin E, Testosterone Pellets; Drug
Lead sponsor: Men's Health Boston; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Infertility, Decreased Ovarian Reserve
Interventions: Dehydroepiandrosterone; Dietary Supplement
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 40 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypogonadism
Interventions: Oral Testosterone Undecanoate, Axiron Testosterone Topical Solution; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 60 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cachexia
Interventions: Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypogonadism, Kallmann Syndrome
Interventions: Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH); Procedure · Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcopenia, Hypogonadism, Muscular Diseases
Interventions: Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation); Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Recurrent Prostate Cancer
Interventions: Testosterone cypionate, Goserelin, Leuprolide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 63
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 53 more

Conditions: Prostate Cancer
Interventions: GnRh (Leuprolide), Testosterone Gel, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: No intervention; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more

Conditions: Metastatic Prostate Cancer
Interventions: High dose testosterone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more

Conditions: Healthy
Interventions: LowT, Resistance Training, Placebo, HighT; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

DHEA Treatment for Sjogren's Syndrome

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

Metabolomics During Testosterone Therapy

Hormone Replacement in Young Women With Premature Ovarian Failure

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Hormone and Information Processing Study

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

TOM: Testosterone in Older Men With Sarcopenia

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

A Registry for Patients Treated on the Clinical Trial TAX 3503

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

TEAM: Testosterone Supplementation and Exercise in Elderly Men